Halozyme Therapeutics Inc $ 28.46 0.26 (0.92%)
Volume:
643,755
Avg Vol (1m):
1,212,576
Market Cap $:
3.90 Bil
Enterprise Value $:
3.90 Bil
P/E (TTM):
0.00
P/B:
37.17
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.99 | ||
| Equity-to-Asset | 0.2 | ||
| Debt-to-Equity | 3.7 | ||
| Debt-to-EBITDA | -19.71 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 5.23 | ||
| Beneish M-Score | -2.45 | ||
| WACC vs ROIC | |||
Profitability Rank | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -16.77 | ||
| Net Margin % | -22 | ||
| ROE % | -26.09 | ||
| ROA % | -8.36 | ||
| ROC (Joel Greenblatt) % | -32.66 | ||
| 3-Year Revenue Growth Rate | 5.8 | ||
| 3-Year EBITDA Growth Rate | 14.2 | ||
| 3-Year EPS without NRI Growth Rate | 14.9 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 31.03 | ||
| PB Ratio | 37.3 | ||
| PS Ratio | 22.26 | ||
| EV-to-EBIT | -166.42 | ||
| EV-to-EBITDA | -197.75 | ||
| EV-to-Revenue | 21.69 | ||
| Current Ratio | 19.19 | ||
| Quick Ratio | 17.34 | ||
| Days Inventory | 287.44 | ||
| Days Sales Outstanding | 75.64 | ||
| Days Payable | 29.37 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 37.05 | ||
| Price-to-Median-PS-Value | 1.35 | ||
| Earnings Yield (Greenblatt) % | -0.61 |